PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Natalizumab - Multiple sclerosis
PAD Profile : Natalizumab - Multiple sclerosis
Keywords :
MS
Brand Names Include :
Tyruko, Tysabri
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Fampridine
- Fingolimod
- Glatiramer acetate
- Interferon beta
- Naltrexone hydrochloride
- Teriflunomide
- Modafinil
- Cladribine
- Ocrelizumab
- Biotin
- Ponesimod
- Ozanimod
- Peginterferon beta-1a
- Memantine hydrochloride
- Donepezil hydrochloride
- Galantamine
- Rivastigmine
- Diroximal fumarate
- Alemtuzumab
- Dimethyl fumarate
- Ofatumumab
- Siponimod
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
No committee recommendations returned.
Associated BNF Codes
08. Malignant Disease and Immunosuppression
08.02.04. Other immunomodulating drugs